^
    Back
    Association details:
    Biomarker:HR positive
    Cancer:HER2 Negative Breast Cancer
    Drug:paclitaxel (Tubulin inhibitor) +
    Reolysin (pelareorep) (Apoptosis stimulant)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    BRACELET-1 (PrE0113): Inducing an inflammatory phenotype in metastatic HR+/HER2- breast cancer with the oncolytic reovirus pelareorep in combination with paclitaxel and avelumab.

    Published date:
    05/25/2023
    Excerpt:
    This is a randomized phase 2 study in pts with HR+/HER2- metastatic breast cancer….After a safety run-in for Cohort 3, patients were randomized 1:1:1 to PTX-alone (Cohort 1), PTX + pelareorep (Cohort 2), or PTX + pelareorep + avelumab (Cohort 3)….The addition of pelareorep to PTX is an active regimen with a high 6-month PFS rate...
    DOI:
    10.1200/JCO.2023.41.16_suppl.1012
    Trial ID:
    BRACELET-1